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ABSTRACT: Transient permeability enhancers (PEs), such as
caprylate, caprate, and salcaprozate sodium (SNAC), improve the
bioavailability of poorly permeable macromolecular drugs.
However, the effects are variable across individuals and classes of
macromolecular drugs and biologics. Here, we examined the
influence of bile compositions on the ability of membrane
incorporation of three transient PEscaprylate, caprate, and
SNACusing coarse-grained molecular dynamics (CG-MD). The
availability of free PE monomers, which are important near the
absorption site, to become incorporated into the membrane was
higher in fasted-state fluids than that in fed-state fluids. The
simulations also showed that transmembrane perturbation, i.e., insertion of PEs into the membrane, is a key mechanism by which
caprylate and caprate increase permeability. In contrast, SNAC was mainly adsorbed onto the membrane surface, indicating a
different mode of action. Membrane incorporation of caprylate and caprate was also influenced by bile composition, with more
incorporation into fasted- than fed-state fluids. The simulations of transient PE interaction with membranes were further evaluated
using two experimental techniques: the quartz crystal microbalance with dissipation technique and total internal reflection
fluorescence microscopy. The experimental results were in good agreement with the computational simulations. Finally, the kinetics
of membrane insertion was studied with CG-MD. Variation in micelle composition affected the insertion rates of caprate monomer
insertion and expulsion from the micelle surface. In conclusion, this study suggests that the bile composition and the luminal
composition of the intestinal fluid are important factors contributing to the interindividual variability in the absorption of
macromolecular drugs administered with transient PEs.
KEYWORDS: transient permeability enhancers, molecular simulation, coarse-grained molecular dynamics, medium-chain fatty acids,
SNAC, membrane incorporation
1. INTRODUCTION
One of the challenges in drug discovery and development is
the low oral bioavailability of poorly permeable drugs such as
peptides, proteins, and oligonucleotide molecules. One
approach to enhance the absorption of poorly permeable
drugs through the intestinal epithelium is coadministration
with transient permeability enhancers (PEs).1−3 A number of
formulations for oral peptide delivery based on transient PEs
went into clinical trials.4−9 Among the most efficient transient
PEs for poorly permeable molecules are the medium-chain
fatty acids (MCFAs) such as sodium caprate, caprylate, and
MCFA-based enhancers such as salcaprozate sodium (SNAC;
a derivative of caprylate).2,10,11 MCFAs modulate the epithelial
membranes in a mild, transient, and rapidly reversible way12,13
and are therefore ideal to use as transient PEs. They are natural
constituents of food products such as milk, coconut oil, and
dairy triglycerides, and their use as transient PEs has shown no
significant toxicity effect, even on individuals receiving multiple
doses.7,10,14 It was found that the antisense oligonucleotides
when coadministered with caprate to 15 male volunteers
achieved an oral bioavailability of 9.5% compared to the
subcutaneous (SC) injection.7 Oral insulin tablets formulated
with caprate achieved a bioavailability of 1.5−2% compared to
insulin delivered with SC injection.8 A novel oily suspension
containing caprylate for oral delivery of Octreotide was found
to be capable of achieving a relative bioavailability of 2.3%
compared to SC injection in monkeys.9 SNAC, another PE,
which was used as a coformulation strategy with semaglutide
(a therapeutic peptide), increased the absorption of orally
delivered peptides transiently from the stomach and showed a
bioavailability of 1.22% in preclinical dog studies.11 After
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testing the various aspects of oral semaglutide in a total of 10
clinical trials named PIONEER,15−24 semaglutide tablet
Rybelsus was approved by the Food and Drug Administration
(FDA) in 2019.25
However, most transient PE-based dosage forms have not
gone beyond clinical trials mainly due to large interindividual
variability and poor commercial viability.2 To develop products
that are robust and can reproducibly deliver macromolecular
drugs, it is important to understand the fate of the PEs after
oral administration. Currently, the physicochemical aspects of
these PEs, and their interactions and enhancement mecha-
nisms at the molecular level in the intestine, are not well
understood.
In the intestine, excipients such as PEs can interact with
various components of the intestinal fluid. MCFA molecules
self-assemble and form micelles with different shapes, sizes,
and structures above their critical micelle concentration
(CMC) in the aqueous solution.26 Therefore, above the
CMC, the number of free MCFA monomers is reduced. The
CMC of MCFA-based permeability enhancers can be affected
by fasted- and fed-state intestinal fluid components. The
secretion of bile also produces self-assembled colloidal
structures that can form mixed micelles with the MCFAs.
These intestinal colloidal structures typically reduce the CMC
of MCFAs, which subsequently decreases the free concen-
tration of MCFAs available to interact with the enterocytes of
the intestinal wall. The free MCFA monomers near the
absorption site increase the permeability through both
transcellular and paracellular pathways, and therefore, the
intestinal fluid may affect the efficiency of the transient PEs.3
Recently, Roos et al. showed that the absorption of four
different drugs (atenolol, enalaprilat, ketoprofen, and meto-
prolol) administered with different transient PEs in a rat model
is lower in the fed-state simulated intestinal fluid (FeSSIF)
than the fasted-state simulated intestinal fluid (FaSSIF).27
Investigation of FD4 through Caco-2 cells shows that the
presence of FaSSIF components reduces the permeability
enhancing capability of dodecyl-maltoside (DDM).28 DDM’s
capability to promote permeation further diminished in the
presence of FeSSIF. Typically, FeSSIF contains 5−6 times
more phospholipids and bile salts than FaSSIF. The ionic
strength, an important factor for the CMC, of FeSSIF is also
twice as high as the ionic strength of FaSSIF. Therefore, the
interaction of transient PEs with the higher number of mixed
micelles formed in FeSSIF significantly lowers the free PE
monomers, which may affect the drug permeability in the fed
state. A similar discrepancy is also expected for the fasted-state
human intestinal fluid (FaHIF) and fed-state human intestinal
fluid (FeHIF) components. Riethorst et al. characterized
human intestinal fluid (HIF) components in the fasted and fed
states collected from the duodenum from 20 healthy
volunteers.29 Fasted-state intestinal fluids were sampled from
the volunteers after an overnight fasting period of 12 h. Fed-
state intestinal fluids were sampled after ingesting a liquid meal
(400 mL of Ensure Plus) following the fasted state. For each
case, the fluids were sampled every 10 min for a period of 90
min. The mean values of bile salts, phospholipids, and free fatty
acids (FFA) in the FaHIF were 3−5 times lower than those in
the FeHIF. In addition to that, significant interindividual
variability is present within the FaHIF. For FaHIF, the mean
values of total bile salts and phospholipids were 4.40 ± 2.87
and 0.95 ± 0.56 mM, respectively.29 Similarly, the FeHIF also
shows significant variability among the types and amount of
intestinal fluid components. Riethorst et al. also characterized
the colloidal structures present in the human and simulated
intestinal fluid compositions and found large multilamellar
vesicles and lipid droplets in the FeHIF.30 On the other hand,
FaHIF and FaSSIF only contained mixed micelles of various
sizes.
The interaction of these mixed micelles from different
intestinal fluid compositions with the transient PEs is not well
understood at the molecular level. The variation in free PE
monomersat a given concentration in the presence of
physiologically relevant intestinal fluid compositionsmakes
an important piece of information for understanding the
intestinal efficacy of the PEs. Likewise, the influence of
interindividual variability of fluid composition is important for
understanding the final permeability enhancement of macro-
molecular drugs.
Experimental techniques have been used to study the
interaction of various surfactant molecules, mixed micelles, and
cell membranes.31−33 However, it has been difficult to
understand PE interactions with intestinal fluids and cell
membranes at a molecular level with these techniques. An
attractive alternative to experimental measurements is
molecular simulations. Recently, coarse-grained molecular
dynamics (CG-MD) has been used for the study of molecular
aggregation related to PEs, such as the aggregation behavior of
various MCFA molecules,26,34,35 structural details of bile salts
and phospholipids micelles31 as well as the octaethylene glycol
monododecyl ether micelles with different small molecules,36
and the interaction of PE molecules with lipid mem-
branes.37−39 CG-MD has also been used to investigate the
complex micelle kinetics of various surfactant molecules40,41
and bile salts.42
Table 1. Components (in mM) of the Studied Fasted- and Fed-State Human Intestinal Fluids from Five Healthy Volunteers
Used in the Simulations of This Studya
fasted state fed state
BS PL FFA pHb BS PL FFA MG DG TG pH
HV3 6.5 0.4 1.5 6.4 10.8 4.2 11.1 8.2 1.4 0.7 5.8
HV6 1.2 1.0 1.0 7.0 28.0 6.9 13.8 6.4 1.4 0.3 6.5
HV9 6.2 1.8 3.2 6.9 13.6 6.5 44.9 11.8 2.2 0.8 6.5
HV16 1.8 0.8 1.1 6.1 10.7 7.7 38.4 11.2 1.5 0.9 6.4
HV20 3.8 0.5 0.5 6.8 15.4 4.2 27.2 12.1 3.2 1.4 6.5
SIF 3 0.75 6.5 15 3.8 5.0
aThe following abbreviations are used: HV, healthy volunteer; SIF, simulated intestinal fluid; BS, bile salt; PL, phospholipid; FFA, free fatty acid;
MG, monoacylglyceride; DG, diacylglyceride; and TG, triacylglyceride. The data were taken from Riethorst et al.29 bThe pH values mentioned in
the table are also taken from Riethorst et al.29 However, we did not include the effect of pH of the systems in this study.
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The main aim of our study was to quantitatively determine
how variations in the intestinal fluid composition affected the
free transient PE monomers that interacted with the cell
membrane. We also investigated how different transient PEs
interact with model cell membranes to understand, on a
molecular level, their transport to the membrane in the
presence of mixed colloidal structures. We performed CG-MD
simulations to estimate the number of free PE monomers when
PEs are added to systems containing human as well as
simulated intestinal fluids. We also used CG-MD simulations
to investigate the interaction of the PEs with a model cell
membrane in the presence of the different intestinal fluid
compositions. Three transient PEs were used in the
simulations: caprylate, caprate, and SNAC. To evaluate the
simulation of PE interaction with the cell membrane, we also
performed complementary membrane interactions experiments
using the quartz crystal microbalance with dissipation (QCM-
D) technique43 and total internal reflection fluorescence
(TIRF) microscopy.44
2. METHODS
2.1. Composition of Intestinal Fluids. The intestinal
fluid compositions for the simulations and in vitro experiments
are presented in Table 1. Data for the components and
compositions of human intestinal fluid in both fasted and fed
states were taken from the study by Riethorst et al. on human
duodenal fluids from 20 healthy volunteers (HVs).29 We used
the data from five of the HVs in their study, as shown in Table
1. These five were selected to capture as high interindividual
variability in bile components as possible, and we are using the
same numbering of HVs as in the Riethorst et al. study.29,30
Note that this study is limited to the investigation of bile
components, more specifically bile salts and phospholipids, and
the effect on the availability and membrane incorporation of
free PE monomers only. Therefore, for simplicity, we did not
include the effect of pH of the systems.
The bile salts from the HVs presented in Table 1 were
composed of four types: sodium taurocholate (NaTC), sodium
taurodeoxycholate (NaTDC), sodium glycocholate (NaGC),
and sodium glycodeoxycholate (NaGDC). The ratios of these
four bile salts were also obtained from Riethorst et al.29 and are
presented in Table 2. For the simulated intestinal fluid, the
only bile salt species was taurocholate. In total, 95% of the
phospholipids secreted in bile are phosphatidylcholine or
lecithin.45 Therefore, 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phatidylcholine (POPC) and 1,2-dilinoleoyl-sn-glycero-3-phos-
phatidylcholine (DLiPC) were used to represent the
phospholipids of the human and simulated intestinal fluids,
respectively. Oleate (OA) (oleic acid at the deprotonated
state) was used to represent the free fatty acids (FFAs) in the
human intestinal fluid systems since it is the largest portion of
the FFAs observed in the HIFs.29
2.2. Coarse-Gained Molecular Dynamics (CG-MD)
Simulations. The CG-MD simulations were performed
using the Martini force field46,47 for systems containing three
permeability enhancers (caprylate, caprate, and SNAC) and
different intestinal fluid compositions, as presented in Table 1.
For the parameterization of caprylate and caprate molecules,
we modified the existing Martini topology for the FFA as
described and validated in Hossain et al.26 To develop the CG-
SNAC model, we first generated an all-atom SNAC model with
an automated parameterization process using the Charmm
General Force Field (CGenFF) 1.0.0 program.48,49 This
program provides penalty scores associated with partial charges
and torsional bonding; penalty scores within 10−50 are judged
reasonable but require further validation of the model. For the
SNAC all-atom model, the maximum penalty scores were 16
and 43 for the partial charges and torsional bonds, respectively.
The all-atom SNAC topology was therefore further modified
using the force field toolkit developed by Mayne et al.50 The
modified all-atom SNAC topology was then used to obtain the
Martini CG topology following the parameterization of new
molecules described on the Martini website. Parameterization
of different bile salts was based on the Martini cholesterol
topology as described and validated in Clulow et al.31 The
topologies of phospholipid (POPC and DLiPC), oleate,
diacylglyceride, and triacylglyceride molecules in our study
were readily available on the Martini website. The topology of
monoacylglycerides was obtained from the triacylglycerides by
removing two fatty acid chains (positions 1 and 3) from the
triacylglyceride molecule.
MD simulations were performed with Gromacs 2016
software using a 30 fs time step at 37 °C.51 The details of
the CG-MD simulated colloidal structures formed in the
intestinal fluid of the HVs presented in Table 1 have been
reported in a previous study.52 Molecules, representing the
molar concentrations from the five samples, were randomly
distributed in a cubic simulation box of 45 nm side length
using Packmol.53 Micelles were observed to be formed
spontaneously during the 3 μs long simulation. In the current
study, the formed micelles are simulated together with the PEs
(in the deprotonated state with negatively charged head-
groups) and after enclosure of the luminal compartment with
model intestinal membranes. For the simulations with PEs and
intestinal fluids, a cubic box with a side length of 50 nm was
used. Isotropic pressure coupling with a reference pressure of 1
bar (1 bar = 100 kPa) was maintained with the Berendsen
coupling method.54 For the simulations with membranes, we
first simulated the fasted- and fed-state components of the
simulated and human intestinal fluids for 3 μs in a simulation
box with dimensions of 18.5, 18.5, and 22 nm in the x, y, and z
directions, respectively. Then, we added 100 mM each PE at
the end state of the intestinal fluid simulation and performed
the simulation for additional 1 μs to let the system reach
equilibrium.
Next, we placed the simulation box in between two identical
POPC membranes to mimic a realistic system where intestinal
fluids and PE components can only interact with one side of
the membrane (see Supporting Figure 1). The lower
membrane was placed 5 nm from the bottom of the box,
and the upper membrane was placed 12 nm from the top.
Table 2. Ratio of Different Bile Salts for Each of the
Simulated Human Intestinal Fluids Used in This Studya
HIF TC TDC GC GDC
HV3 13.7 23.2 25.5 37.5
HV6 8.3 10.7 30.5 50.4
HV9 10.2 17.9 24.8 47.1
HV16 15.9 33.6 18.0 32.4
HV20 11.5 17.6 28.9 42.0
aAll values are presented as % of the total bile salt mentioned in Table
1. bThe following abbreviations are used: HIF, human intestinal fluid;
TC, taurocholate; TDC, taurodeoxycholate; GC, glycocholate; and
GDC, glycodeoxycholate.
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POPC was selected as the model lipid since phosphatidylcho-
line is a common phospholipid found in the plasma membrane
of intestinal epithelial cells.55 The POPC membrane was
generated using the method Insane developed by Wassenaar et
al.56 For each membrane, 1058 POPC molecules were used
with 529 molecules in each leaflet. The resulting bilayer from
Insane was then equilibrated and used in the simulations. The
thickness of the formed bilayer and the area per lipid for the
equilibrated membrane were 4.05 nm and 0.64 nm2,
respectively, at 37 °C. These values are close to the
experimentally measured ones for the POPC membrane.57
The overall dimensions of the system became 18.5, 18.5, and
50 nm in the x, y, and z directions, respectively. The
simulations were then performed for another 6 μs with semi-
isotropic pressure coupling. Note that a smaller box size was
used for the systems with membranes because we wanted to
run longer simulations. Each system was energy-minimized
using the steepest descent algorithm, followed by four short
equilibration runs (50 000 steps) with time steps of 1, 2, 5, and
20 fs, before the final production run. A periodic boundary
condition was also applied for all of the simulations.
We calculated the number of micelles and free monomers
using in-house python code. Two molecules were considered
to be in the same micelle if their constituent beads were within
a specific cutoff distance. For the Martini model, this cutoff
distance was determined to be 0.6 nm.58 To calculate the
monomer insertion and expulsion events, we mapped all
molecules into two different statesaggregated or freeat
each time step. We then detected the molecules that changed
their state between two consecutive saved configurations.
Molecules that changed their state from aggregated to free
were considered as expulsion events, and those that changed
their state from free to aggregated were considered as insertion
events. Note that in this approach we did not identify whether
a molecule transferred from one micelle to another. However,
since we used a smaller time step (5 ns) between two saved
configurations, the occurrence of such an event, which includes
the detachment of the C10 molecule from one micelle and
then reattachment to another micelle, was considered highly
unlikely and thus negligible.
2.3. Umbrella Sampling (US) Simulations. The
potential of mean force (PMF) profiles were computed for
caprate monomer expulsion from the micelle surface to the
water phase using umbrella sampling (US) simulations.59 We
first generated four different micelles for the US simulations
(see Supporting Table 1 for the compositions). To generate
the micelles, we placed the molecules constituting the micelles
close to each other in a cubic box with a 5 nm side length using
Packmol.53 After energy minimization and equilibration, we
performed a 100 ns production run and the micelles were
formed with the caprate monomer present near the shell region
in each case. To perform the US simulations, a series of
configurations were generated along the reaction coordinate
that, in this case, was the distance from the micelle shell to the
bulk water phase. We generated 20 configurations separated at
a distance of 0.1 nm along the reaction coordinate. Each
configuration served as the starting point for the US
simulations and was energy-minimized, equilibrated for 2 ns,
followed by a production run for 20 ns. To extract the
potential of mean force (PMF) along the reaction coordinate
from the US simulations, the weighted histogram analysis
method (WHAM) implemented in Gromacs as gmx wham
utility was used.60 Statistical errors were estimated from
bootstrap analysis over 100 runs using a tolerance of 1 × 10−5.
For comparison and further validation of the CG-SNAC
parameters, US simulations were also performed to compute
the PMF profile for pulling caprate and SNAC molecules from
the membrane center to water phase using the all-atom
Charmm force field.61 The all-atom POPC membrane was
generated using the CHARMM-GUI membrane builder.62
2.4. Quartz Crystal Microbalance with Dissipation
(QCM-D) Monitoring. QCM-D measurements were per-
formed on silicon dioxide-coated QSX 303 QCM-D sensors
mounted in a Q-Sense E4 system (Biolin Scientific AB,
Sweden). The sensor and solution chambers were maintained
at 37 ± 0.1 °C for the duration of the experiments, and the
third, fifth, and seventh harmonics were recorded simulta-
neously for data collection. The sensors were first flushed with
Tris buffer (10 mM Tris, 125 mM NaCl, 1 mM Na2EDTA, pH
7.4 adjusted with HCl) at a flow rate of 50 μL/min. POPC
membrane formation was monitored for ∼10 min by
incubating POPC (Avanti Lipids) vesicles (0.1 mg/mL in
Tris buffer) at a continuous flow. Following rinsing, the POPC
membrane was exposed to various simulated intestinal fluid
conditions, with or without the presence of PEs (Supporting
Table 2), for ∼30 min to allow time for the intestinal fluid
components to interact with the membrane. The system was
again rinsed to observe the final changes in frequency (Δf) and
dissipation (ΔD).
2.5. Total Internal Reflection Fluorescence (TIRF)
Microscopy. Total internal reflection fluorescence (TIRF)
microscopy was performed on an inverted Eclipse Ti-E
microscope (Nikon Corporation) equipped with a Perfect
Focus System (PFS), a CFI Apo TIRF 100× oil objective (NA
1.49), a high-pressure mercury lamp, and an Andor Neo SCC-
01322 sCMOS camera (Andor Technology). Lipid mem-
branes were formed on a glass microscopy slide (0.13−0.16
mm thickness) in custom-made polydimethylsiloxane wells
with a volume of ∼50 μL by incubating POPC vesicles (0.1
mg/mL, 10 μL) mixed with lissamine rhodamine B sulfonyl
(Rh-PE, Avanti Lipids) vesicles at a ratio of 1:100. A
rhodamine filter set (TRITC, Semrock) was used for
visualizing the lipid membrane or POPC/Rh-PE vesicles.
Lipid membrane formation was confirmed by fluorescent
recovery after photobleaching (FRAP), i.e., by bleaching the
rhodamine tracer lipids with a Kr−Ar mixed gas ion laser
(Stabilite 2018, Spectra-Physics Lasers, Mountain View, CA)
at a wavelength of 531 nm. The diffusivity of Rh-PE within the
membrane was determined using a custom-written analysis
software in MATLAB (MathWorks), as described by Jönsson
et al.63
The impact of each PE on lipid membrane diffusivity was
first established by preincubating the POPC/Rh-PE mix at
various concentrations (5−80 mM) of caprylate, caprate, or
SNAC, prior to membrane formation. POPC/Rh-PE/PE
mixed vesicles (10 μL) were then deposited onto the glass
substrate and lipid membrane formation was monitored with
TIRF microscopy. The formed lipid membranes were
subsequently rinsed with either buffer, FaSSIF, or FeSSIF to
remove any unbound vesicles. FRAP analysis was performed in
triplicate on the lipid membrane at each PE concentration,
enabling the PE concentration-dependent membrane diffusiv-
ity to be derived.
Once the impact of PE incorporation on membrane
diffusivity was established, POPC/Rh-PE vesicles (10 μL; in
the absence of PEs) were deposited onto a glass substrate to
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form POPC bilayers. The POPC membrane was rinsed with
Tris buffer to remove the unbound vesicles and then exposed
to various SIF conditions, with or without PEs (Supporting
Table 2), for 30 min. FRAP analysis was again performed on
the membrane to determine any incubation effects in the SIF
conditions on lipid diffusivity. It was assumed that any changes
in membrane diffusivity, compared to a pure POPC
membrane, were due to the incorporation of PEs within the
lipid membrane.
2.6. Statistical Analysis. Statistics were performed by one-
way analysis of variance (ANOVA) using Tukey’s posthoc test
for multicomparison between the groups. All calculations were
carried out using GraphPad Prism Version 8.2.1 (GraphPad
Software Inc.).
3. RESULTS AND DISCUSSIONS
3.1. Interactions of Transient Permeability Enhancers
(PEs) with Intestinal Fluids (IFs). The components of
intestinal fluids form colloidal structures of various sizes and
shapes. Excipients such as transient PEs may interact with the
intestinal fluids as well as the mixed colloidal structures. In this
study, we therefore simulated the FaHIFs from five healthy
volunteers, as well as FaSSIF to investigate whether the
variation in their components can influence the availability of
free PE monomers. This was done as FaSSIF is a very common
substitute solvent for FaHIF in experimental studies and we
wanted to analyze potential similarities and differences of
FaSSIF with FaHIFs in interactions with PE. We used a cubic
simulation box with a side length of ∼50 nm and performed
each simulation for 3 μs to allow the systems to reach an
equilibrated state. To evaluate whether the system has reached
equilibrium, we observed the variation in the number of
micelles with the simulation time that was reported in our
previous study. We found none or very few dynamic changes
using this measure in the last 0.5−1 μs and hence concluded
that the systems had reached equilibrium.52
For each human and simulated intestinal fluid, the numbers
of mixed micelles and free bile salt monomers at the end of the
simulation were different from each other due to the variation
in the fluid composition. Figure 1A,B shows the snapshots of
simulations at 3 μs with FaHIF from healthy volunteers HV3
and HV6. Note that in our simulations, HV3 and HV6 had the
highest and lowest amount of bile salts, respectively, in the
FaHIF compositions. In line with our previous study, Figure
1A,B shows the difference in number of mixed micelles and the
available free bile salt monomers for the two volunteers, as a
result of the variability in their FaHIF compositions.52 The size
of micelles formed during the simulation ranged between 2.3
and 7.3 nm.
With each equilibrated system of intestinal fluid compo-
nents, we added two concentrations of caprate: 20 mM, which
is close to its CMC in water in the absence of ionic strength,26
and 100 mM, which is typically used in vivo studies to
overcome the physiological variability.5 The aim of this study
was to explore a low concentration (20 mM) and a high
concentration (100 mM) to understand the impact of dilution
in the small intestine. While local high concentration may be
reached, i.e., at the 100 mM scale, dilution may quickly lower
the concentrations used and hence the membrane interaction
pattern may be changed. The simulations were run an
additional 1 μs after the addition of the caprate to the already
equilibrated HIFs, mimicking dispersion of PEs into the
intestinal fluid after ingestion of e.g., a PE-containing tablet or
capsule. To evaluate whether the system has reached
equilibrium with respect to the available free caprate
monomers, variations in the number of free caprate monomers
Figure 1. Colloidal structures from the simulations with fasted-state human intestinal fluids (FaHIFs) and caprate. (A, B) Representative snapshots
of simulations with FaHIFs from two healthy volunteers (HV3 and HV6, respectively) at 3 μs. Snapshot of the simulations for the same volunteers
at 1 μs with 20 mM (C, D) and 100 mM (E, F) caprate added to the FaHIF simulations at 3 μs shown in (A, B). The amount of free caprate
monomers at the end of simulations with the addition of (G) 20 mM and (H) 100 mM caprate. Each bar represents the average monomer
concentration with the standard deviation (n = 3). Statistical significance was defined as p ≤ 0.05 for the one-way ANOVA test. Here, p < 0.01 and
p < 0.001 are denoted with ** and ***, respectively. Note that for clarity, only p < 0.001 is shown in (G). In (H), only FeSSIF was statistically
different from the other sample (p < 0.01, indicated by **). Abbreviations used: TC, taurocholate; TDC, taurodeoxycholate; GC, glycocholate;
GDC, glycodeoxycholate; OA, oleate; PL, phospholipids; HV, human volunteer; FaSSIF, fasted-state simulated intestinal fluid; and FeSSIF, fed-
state simulated intestinal fluid.
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were estimated during the simulation (Supporting Figure 2).
The number of free caprate molecules reduces during the
simulations and reached a plateau after 0.60 and 0.15 μs when
20 and 100 mM of caprate were added, respectively.
During the simulation, the added caprate monomers
interacted with the existing mixed micelles or free bile salt
monomers and either (i) coalesced with the existing micelles,
(ii) formed new mixed micelles, or (iii) formed pure caprate
micelles (Figure 1). Figure 1C,D shows simulations snapshots
for HV3 and HV6 at 1 μs with 20 mM of caprate. The
snapshots indicate that the number of free caprate monomers
for HV6 was higher than for HV3, mainly because the FaHIF
of HV6 contained fewer mixed micelles and free bile salt
monomers as shown in Figure 1B. Therefore, the interaction of
the caprate with the intestinal components was lower in HV6
than HV3, resulting in a higher number of free caprate
monomers for HV6.
The sizes of the micelles formed during the simulations for
all cases are summarized in Supporting Table 3. In our
previous study, we reported that the size of the micelles formed
with the fasted-state intestinal components alone ranged
between 2.3 and 7.3 nm.52 The reported sizes were close to
the lower fraction of the mixed micelles observed exper-
imentally (10−50 nm).30 In this study, the size of the micelles
is found to be ranged between 2.7 and 13.3 nm with averages
between 4.1 and 5.6 nm when different concentrations of PEs
are added. The increase in the maximum micelle size was due
to the addition of caprate molecules. We also plotted the
distribution of the aggregate sizes for all cases expressed as the
aggregation number, N (Supporting Figure 3). When 20 mM
caprate were added in the systems, we observed a larger peak
in the range of N = 20−25 and a number of smaller peaks
higher than N = 40. However, for each case, the location of the
peaks and the number of peaks were different. This indicates
the difference in micelle sizes among different intestinal fluids
due to the variation in the fluid components. However, when
100 mM caprate was added, for all cases, the distribution
profile was very similar. We mainly observe a single peak near
N = 35, which corresponds to the average aggregation number
for caprate alone, which is typically in the range of 34−47
measured experimentally.32,64 This suggests that, with the
addition of 100 mM caprate, the systems were mainly
dominated by caprate.
We then determined the amount of free caprate monomers
at the end of the 1 μs simulation for all cases, and Figure 1G
shows the results when 20 mM caprate were added to the
systems. The number of free caprate monomers was
significantly different for each case because of the variability
in the number of mixed micelles and available free bile salt
monomers at the end of simulations with intestinal fluids
alone. In general, the systems that contained a higher amount
of intestinal fluid components had a lower number of available
free caprate monomers.
When 100 mM caprate was added, the snapshots at 1 μs for
HV3 (Figure 1E) and HV6 (Figure 1F) showed no differences.
With 100 mM caprate, the system was so dominated by
caprate molecules that variations in the fasted-state intestinal
fluids became negligible. Figure 1H shows the free caprate
monomers at the end of the 1 μs simulation after the addition
of 100 mM caprate. The available free caprate monomers were
very similar to each other. Only the value for the caprate
addition to FeSSIF was statistically different from the other
intestinal fluids. On the other hand, the results here indicate
that the fasted-state interindividual variability significantly
affected the availability of the free caprate monomers at caprate
concentrations near its CMC (Figure 1G). However, the
difference in the fasted- and fed-state compositions clearly
impacted the number of free caprate monomers irrespective of
the added caprate concentrations, with fewer caprate molecules
being freely dissolved in the aqueous phase in the fed state. To
further increase our understanding of the PEs intestinal
performance, we continued investigating the PE interaction
with the intestinal fluids in the presence of cell membranes to
mimic more realistic in vivo conditions.
3.2. Amount of the Transient Permeability Enhancer
That Reaches the Membrane. To investigate the PEs
interaction with the membrane, as described in Section 2.2, we
placed the components of the intestinal fluid and 100 mM
caprate in between two POPC membranes. Note that such a
high concentration of caprate achieved in the GI lumen can be
quickly diluted. However, it is important to understand the
effect of such a high concentration on the membrane
incorporation ability of caprate in the presence of fasted- and
fed-state intestinal fluids. The simulations were performed for
only 6 μs, and Figure 2 shows the initial snapshots of the
system with POPC membranes and 100 mM caprate added to
the FaHIF (Figure 2A) and FeHIF (Figure 2C) of HV3. Both
snapshots indicate a number of mixed micelles and free caprate
monomers in between the membranes. The mixed micelles in
Figure 2. Interaction of 100 mM caprate in the presence of POPC
membranes. Fasted-state human intestinal fluid (FaHIF; A and B),
and fed-state human intestinal fluid (FeHIF; C and D) from human
volunteer 3. Snapshots of the simulations at the initial and final time
steps with (A, B) FaHIF and (C, D) FeHIF components placed
between the two membranes. Abbreviations: TC, taurocholate; TDC,
taurodeoxycholate; GC, glycocholate; GDC, glycodeoxycholate; OA,
oleate; PL, phospholipid; MG, monoacylglyceride; DG, diacylglycer-
ide; and TG, triacylglyceride.
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the system with fed-state components were larger than in the
fasted-state system. This is mainly due to the large difference in
the compositions of the fasted- and fed-state fluids; for HV3,
the sum of all of the intestinal fluid components was five times
higher in FeHIF than that in FaHIF (Table 1). During the
simulations, the caprate monomers interacted with the mixed
micelles as well as the lipid membranes. The system is highly
dynamic. During the simulations, it becomes evident that
caprate, after insertion into the mixed micelles, also can be
released into the aqueous phase as free monomers. The free
monomers then can come in contact with other mixed
micelles, remain as free monomers, or get inserted into the cell
membrane. Figure 2B,D shows the final snapshots of the
simulations with FaHIF and FeHIF of HV3. The number of
caprate monomers inserted into the membrane was higher in
the simulation with FaHIF (Figure 2B) than that with FeHIF
(Figure 2D). Table 3 shows the calculated caprate molecules
inserted into the membrane at the end of a 6 μs simulation for
each intestinal fluid condition. The number of inserted
caprates after the simulation was 1.7−2.6 times higher in the
fasted-state fluid components than that in the fed-state
components. This suggests that the systems with fasted-state
fluids allow more caprate to interact with the membrane, which
in turn increases the caprate incorporation in the membrane.
Interestingly, despite adding a higher caprate concentration
(100 mM) into the system, we found a large discrepancy in the
amount of inserted caprate for different fasted-state fluid
compositions. Note that in the fasted-state intestinal fluids with
100 mM caprate, the amount of available free caprate
monomers was not different compared to each other as
discussed in Section 3.1. However, with a membrane,
variations in the fasted-state fluids become crucial because
the membrane can extract caprate and hence substantially
decrease its concentration in the aqueous phase. The amount
of inserted caprate for different fed-state fluid compositions
was also different when compared to each other. This is mainly
due to the large variation in the fluid components as well as the
decrease of caprate concentration in the aqueous phase during
the simulation.
We also investigated the interaction of caprylate and SNAC
with FaSSIF and FeSSIF between the POPC membranes.
Caprylate performed similarly to caprate. During the
simulations, caprylate molecules were inserted into the
membrane and the number of inserted caprylate molecules
was ∼1.8 times higher for FaSSIF than that for FeSSIF. Figure
3 shows how the PE molecules varied in their interactions with
the membrane during the simulation. The simulations of
FaSSIF with caprylate and caprate (Figure 3A) showed that
the rate of insertion into the lipid bilayer plateaued faster for
caprylate (2.8 μs) than that for caprate (5.8 μs). This kinetic
difference is because the CMC of caprylate is higher than that
of caprate, and therefore, a greater number of free caprylate
monomers are immediately available to interact with the
membrane. Note that the higher insertion rate does not
necessarily mean that caprylate will be more efficacious than
caprate. The increase in membrane fluidity is also related to
the fatty acid chain length, meaning that the concentration
required to increase the cell membrane fluidity decreases with
the chain length.65 The profiles of the FeSSIF simulations with
caprylate and caprate were similar, i.e., both compounds had
similar kinetics with similar fractions being inserted (Figure
3B). The profiles of caprate and caprylate insertion increased
continuously with time (Figure 3A,B), which suggests that,
once inserted, the caprate and caprylate molecules remain in
the membrane for the duration of the simulation period.
The interaction of SNAC with the membrane was different
from those of caprylate and caprate in the simulation with
FaSSIF and FeSSIF. The SNAC profile quickly plateaued, i.e.,
the SNAC molecules reached the maximum level that could
interact with the membrane. The plateau was reached within
less than 0.15 μs and was thereafter oscillating during the
simulation. From Figure 3, it is also evident that fewer
molecules of SNAC than those of caprylate and caprate were
adsorbed onto and incorporated into the membrane surface.
The amount of SNAC molecules that interacted with the
membrane was about 1.3 times higher for FaSSIF than that for
FeSSIF. During the simulations, we also observed that the
taurocholate molecules are absorbed on the membrane surface
and occupy the membrane surface area. The relatively lower
insertion of SNAC for FeSSIF is mainly due to the competition
with a higher amount of taurocholate present in FeSSIF.
We then investigated the adsorption onto or insertion of
caprate and SNAC molecules into the membrane. We
calculated the average distance, d, between the membrane
Table 3. Percentage and Standard Deviation of the
Transient Permeability Enhancer (PE) Inserted into or
Adsorbed onto the Membrane Surface by the End of a 6 μs
Simulationa
PE intestinal fluid fasted state fed state
caprate HV3 77.0 ± 0.6 44.7 ± 0.6
HV6 81.4 ± 0.2 31.5 ± 0.1
HV9 71.3 ± 0.2 40.2 ± 0.2
HV16 82.0 ± 0.5 46.7 ± 0.2
HV20 74.3 ± 0.5 39.5 ± 0.4
simulated 83.6 ± 0.3 50.7 ± 0.2
caprylate simulated 94.3 ± 0.3 51.0 ± 0.4
SNAC simulated 25.2 ± 1.6 19.8 ± 1.4
aData is shown as mean ± SD, where mean and SD were obtained by
averaging the last 30 snapshots within 5.8−6.0 μs of the simulation
time. Abbreviation: HV, human volunteer.
Figure 3. Inserted and adsorbed molecules of transient permeability
enhancers (PE) on the membrane surface when 100 mM PEs is added
in the systems with (A) fasted-state simulated intestinal fluid and (B)
fed-state simulated intestinal fluid (n = 1).
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center (along membrane normal direction) and the center of
mass for both caprate and SNAC molecules that were adsorbed
on or inserted into the membrane (Supporting Figure 4b). The
value of d was 1.4 nm for caprate and 1.9 nm for SNAC
molecules, indicating that the center of mass of the caprate
molecules was deeper inside the membrane leaflet than that of
the SNAC molecules. We then calculated the average lipid tail
order parameters, P2, for the inserted or absorbed fatty acid
chains using the following equation
P 0.5(3 cos 1)2
2 θ= ⟨ ⟩ −
where θ is the angle between the membrane normal or the z-
axis of the simulation box and the vector from two consecutive
beads of the fatty acid chain (Supporting Figure 4). Note that
P2 = 1 means a perfect alignment of the fatty acid chain with
the z-axis and P2 = 0 means a random orientation. The P2
values for caprate were 0.6 and 0.15 for SNAC, suggesting that
the SNAC molecules were mostly randomly oriented on the
membrane surface, while the caprate molecules were mostly
aligned with the z-axis. Overall, the values of d and P2 suggest
that the caprate molecules are incorporated into the membrane
during the simulation, while SNAC molecules are mostly
adsorbed on the membrane surface. From this adsorbed
position, they could interact either with the membrane or the
aqueous phase. This is also evident in Figure 4A,B that shows
the different interaction behaviors of caprate and SNAC with
the membrane, respectively. Hence, our results indicate that
transcellular perturbation is not the key mechanism for SNAC,
whereas it is a likely mechanism of how caprylate and caprate
increase permeability.
To verify the CG simulation results, we also performed
umbrella sampling simulations using all-atom force fields
(Section 2.3) to obtain PMF profiles associated with the
pulling of caprate and SNAC molecules from the membrane
center to the water phase. The free energy profiles are
presented in Figure 4C. From the profiles, we calculated the
energy minima, which were at 1.46 and 1.93 nm from the
membrane center for caprate and SNAC profiles, respectively.
The energy minima here represent the maximum probability of
finding the molecules along the membrane normal direction.
Interestingly, this energy minima correspond well with the
calculated average distance, d, obtained from the CG
simulations. Note that the value of d was 1.4 nm for caprate
and 1.9 nm for SNAC molecules, respectively. Also, below the
membrane headgroup region (<1.9 nm), the caprate profile
always has a lower value compared to the SNAC profile.
Hence, similar to the findings from CG simulations, the all-
atom PMF profiles also indicated different interaction patterns
for caprate and SNAC with the POPC membrane.
These findingsthat SNAC is merely adsorbed on the
surface of the membrane, whereas the caprate molecules are
inserted into the bilayersare in agreement with the literature.
The in vitro and in vivo studies of the mode of action of caprate
to improve permeability suggest that, at low concentrations,
the enhancer molecules act on tight junctions and mainly
enhance permeability using paracellular pathways.13,65−67At
higher concentrations, caprate primarily promotes transcellular
permeability by membrane perturbation.2 On the other hand,
various mechanisms are proposed in the literature for how
SNAC promotes permeability. Some studies suggest that
SNAC improves passive transcellular permeability by forming a
noncovalent complex with the drug molecules.68 Another
study shows that SNAC increases the absorption of
semaglutide in the stomach by increasing the local pH around
the semaglutide peptide.11 It has also been implied that
membrane insertion is unfavorable for SNAC due to the
hydrophilic functional group of the salicylamide region.2 In a
recent study by Twarog et al., the mechanisms of action of
caprate and SNAC were investigated using the Caco-2 assay.
They suggested that SNAC was less potent than caprate at
Figure 4. Transient permeability enhancers (PEs) inserted into and adsorbed on the membrane. (A) Caprate inserted (mostly aligned vertically
with the POPC molecules) into the membrane and (B) SNAC adsorbed on the membrane surface. The black circle indicates a SNAC molecule
adsorbed (laying horizontally) on the membrane surface. In (A) and (B), the POPC molecules of the membrane are shown as bonded lines;
caprate and SNAC are represented by beads. The blue, orange, and pink beads represent the headgroup, fatty acid chain, and salicylamide region,
respectively. (C) PMF profiles obtained using all-atom molecular dynamics simulations, depicting the energy required to pull the PE molecules
from the membrane center to the aqueous phase. In the PMF profiles, the lines and shaded regions represent the means and standard deviations,
respectively, of triplicate simulations.
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inducing plasma membrane perturbation associated with
membrane permeabilization.69 Indeed, this was observed in
our simulations, where SNAC were randomly adsorbed onto
the surface rather than being inserted into the phospholipid
bilayer.
For the fed-state compositions, large-scale colloidal
structures (i.e., droplets or large vesicles) in the scale of
micrometers are also observed in experimental studies.30 The
system size of the CG-MD simulations performed in this study
was not large enough to observe such large-scale structures.
Note that, although in the simulations with fed-state
components do not produce the full range of colloidal
structures typically present in the intestine, the simulations
were still capable of elucidating the higher amount of caprate
incorporation into the membrane in the fasted state than that
in the fed state. Another simplification made in the current
study is to compose a membrane of POPC only, while a typical
intestinal membrane is composed of a mixture of different
phospholipids and cholesterol. To which extent the variation in
membrane composition further impacts caprate interaction
with membrane requires further exploration and experimental
validation.
3.3. Investigating the Interaction between PEs and a
Lipid Membrane in the Presence of Intestinal Fluids
Using QCM-D. The interaction between PEs (dispersed in
FaSSIF and FeSSIF) and a lipid membrane was experimentally
assessed using QCM-D (Figure 5). Briefly, QCM-D affords the
ability to monitor the mass and structural changes of thin films
adsorbed on the quartz crystal surface through changes in the
frequency, f, and dissipation energy, D; where f relates to the
mass of the adsorbed material (i.e., decreasing f = increasing
mass adsorbed) and D relates to the film elasticity/rigidity (i.e.,
increasing D = increasing viscoelasticity).43 First, lipid bilayer
formation was monitored and confirmed, prior to exposure of
the membrane to PEs, as demonstrated through characteristic
changes in f and D for bilayer formation, shown previously.43
That is, POPC vesicle adsorption on the silica substrate was
identified after 7−8 min by an initial decrease in f, coupled
with an increase in D (Figure 5, step i). The membrane
formation was evidenced by a subsequent increase in f, coupled
with a decrease in D, due to the vesicles rupturing and forming
a rigid lipid bilayer on the sensor surface. In each case, the f
and D changes corresponding to the membrane formation
were ∼−25 Hz and 0.1 × 10−6 (third overtone), respectively,
consistent with previous findings.43 After a buffer rinse to
remove the unbound lipid vesicles, only minor changes in f and
D profiles were observed.
After 20 min, the POPC membranes were exposed to a
continuous flow of FaSSIF or FeSSIF in the presence or
absence of 100 mM caprylate, caprate, or SNAC. A
comparison of Figure 5A with B shows a greater initial
decrease in the frequency for FeSSIF than that for FaSSIF (in
the absence of PEs), which indicates greater colloidal vesicle
adsorption onto the lipid membrane for FeSSIF, likely due to
the increased concentration of micellar species. Further
evidence of this was a greater change in dissipation for
FeSSIF, demonstrating the viscoelastic adsorption of mobile
vesicles.43 After a final buffer rinse, the change in frequency
was twofold greater for FeSSIF than that for FaSSIF,
suggesting more lipid transfer from the colloidal vesicles to
the lipid membrane. For both FaSSIF and FeSSIF, only a small
final change in dissipation was observed, meaning that the
structural integrity of the lipid membrane was mostly
maintained.
A comparison of the QCM-D profiles for FaSSIF and
FeSSIF in the presence of PEs showed the variations in the
adsorption mechanisms for each PE. Here, the FaSSIF and
FeSSIF were preincubated with each PE, and thus, it was
predicted that three micelle/vesicle population groups existed
(as observed in CG-MD simulations): (i) mixed micelles/
vesicles with PE included, (ii) mixed micelles/vesicles with
only phospholipids and bile salts (i.e., no PE), and (iii) pure PE
micelles. When 100 mM caprylate was included within FaSSIF
and FeSSIF, a two-step spontaneous adsorption/fusion process
was observed. Here, there was a large decrease in frequency
(−48.4 Hz for FaSSIF and −27.2 Hz for FeSSIF) and an
increase in dissipation. This indicates that viscoelastic vesicle
adsorption onto the lipid bilayer was followed by a rapid
increase in frequency and decrease in dissipation due to vesicle
fusion within the bilayer. Put another way, the QCM-D profiles
suggested that caprylate-rich micelles/vesicles first adsorbed
onto the POPC membrane before their complete incorpo-
ration within the membrane. Since this two-phase adsorption/
fusion mechanism was not evident for FaSSIF and FeSSIF in
the absence of caprylate, it suggests that the fusion process is
controlled by those micelles/vesicles that were mostly
composed of caprylate. Furthermore, the final changes in
Figure 5. Frequency and dissipation changes at the third, fifth, and
seventh harmonics at different stages of QCM-D monitoring. The
following procedure was used: (i) addition of 0.1 mg/mL POPC
vesicles in Tris buffer to the Q-Sense system; (ii) rinse with Tris
buffer; (iii) addition of the fasted-state simulated intestinal fluid or
fed-state simulated intestinal fluid in the absence (A, B) or presence
(C−H) of permeability enhancers caprylate (C8), caprate (C10), and
SNAC; and (iv) final rinse with Tris buffer.
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frequency and dissipation (after a buffer rinse) highlight
differences in the extent of caprylate bilayer fusion in the fed
state versus fasted state, with the fasted state having a greater
negative frequency (Figure 6).
QCM-D observations indicated that the adsorption and
fusion mechanism for caprate varies considerably between the
fed and fasted states. In the fasted state, caprate revealed a less
pronounced two-step adsorption and fusion step, where the
initial decrease and increase in f and D, respectively (due to
vesicle adsorption), was followed by a small and prolonged
increase and decrease in f and D, respectively. The rate and
extent of this fusion step were considerably reduced compared
to the fusion of caprylate-rich micelles/vesicles with the lipid
membrane. In the fed state, however, QCM-D profiles were
representative of viscoelastic adsorption of micelles/vesicles,
without evidence of a clear fusion step. This suggests that
under these conditions, caprate-rich vesicles adsorb onto the
lipid bilayer, but the reduced availability of free caprate
monomers limits the potential for membrane perturbation.
The final rinse with Tris buffer removed any adsorbed vesicles
on the surface of the membrane, as evidenced by an increase in
f and a decrease in D. Importantly, the final change in
frequency for caprate in the fasted state was >2-fold greater
than in the fed state (Figure 6). This directly supports our CG-
MD simulations and our hypothesis that greater exposure of
caprate to the lipid membrane is induced in the fasted state.
CG-MD simulations indicated that SNAC only adsorbed
onto the lipid membrane, without the presence of membrane
perturbation, which was supported by one-step viscoelastic
adsorption QCM-D profiles in FaSSIF and FeSSIF. SNAC also
triggered a positive change in frequency in both FaSSIF and
FeSSIF, which suggests that the final mass adsorbed onto the
QCM-D sensor was reduced after exposure to SNAC.
Furthermore, the change in dissipation for SNAC in the fed
state was 4−16-fold greater than the dissipation change for
FeSSIF in the presence of caprylate and caprate, respectively,
indicating that a highly viscoelastic adsorbed layer formed for
lipid membranes exposed to SNAC. These findings indicate
that SNAC (i) poorly inserted into the lipid membrane,
potentially due to a reduced affinity for the membrane, (ii)
adsorbed onto the lipid membrane surface in a nonrigid
manner, and/or (iii) altered the lipid packing density within
the membrane due to its larger molecular size and spatial
orientation compared to the translocated POPC molecules
(and caprylate and caprate molecules), thus reducing the
adsorbed mass and increasing membrane viscoelasticity.
3.4. Impact of PEs on Lipid Bilayer Diffusivity Studied
by TIRF Microscopy. FRAP analysis was used to quantify the
lipid mobility and diffusivity within a lipid bilayer supported on
a silica substrate by monitoring the rate of recovery of a
photobleached hole within the lipid membrane (Figure 7). The
first step was to establish and validate the role of PE
incorporation into lipid membranes in lipid diffusivity. To
achieve this, various concentrations of PEs were preincubated
with fluorescently labeled POPC vesicles prior to membrane
formation. The POPC−PE mixed vesicles were deposited onto
a glass substrate, which triggered vesicle fusion and the
creation of POPC−PE mixed membranes. The known
concentrations of PEs used for lipid bilayer formation ranged
between 5 and 80 mM since bilayer formation was not possible
Figure 6. Final changes in the frequency (Δf) and dissipation (ΔD)
for permeability enhancers caprylate (C8), caprate (C10), and
salcaprozate sodium (SNAC) were studied in the presence or absence
of (A) fasted-state simulated intestinal fluid or (B) fed-state simulated
intestinal fluid. The change was obtained by subtracting the frequency
and dissipation values at the end of step (iv) from the values at the
end of step (ii).
Figure 7. PE concentration-dependent diffusivity of lipid membranes.
Varying concentrations of caprylate (C8; A), caprate (C10; B), and
SNAC (C) were preincubated with POPC prior to lipid membrane
formation. The resultant hybrid POPC−PE lipid membranes were
then rinsed with buffer, fasted-state simulated intestinal fluid
(FaSSIF), or fed-state simulated intestinal fluid (FeSSIF), and the
diffusivity was measured using FRAP analysis. Following this, pure
POPC membranes were formed and incubated with 100 mM PE in
FaSSIF and FeSSIF. After 30 min incubation, FRAP analysis was
performed, and diffusivity measurements of the incubated membranes
are shown in (D) and (E), respectively. Data represents mean ± SD
(n = 3). (F) TIRF micrographs demonstrating the fluorescent
recovery of a bleached hole within the lipid bilayer incubated with
buffer and no PEs. Scale bars: 20 μm.
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for all PEs at concentrations exceeding 80 mM. A PE
concentration-dependent effect on lipid membrane diffusivity
was evident for caprylate, caprate, and SNAC (Figure 7A−C).
That is, lipid diffusivity increased in a linear concentration-
dependent manner for increasing concentrations of caprylate
(Figure 7A) and caprate (Figure 7B), after the lipid membrane
was rinsed with buffer, FaSSIF, and FeSSIF. This is in
agreement with previous studies that demonstrate that the
insertion of saturated fatty acids into lipid membranes
increases packing density and the reduced molecular size of
lipids reduces membrane viscosity.70,71 Subsequently, the
kinetic and thermal energy required to promote lipid mobility
is also reduced.72 In contrast, lipid diffusivity decreased in a
concentration-dependent manner, in all conditions, when
hybrid membranes were formed with SNAC and POPC
(Figure 7C). It has been hypothesized that the steric hindrance
associated with the larger molecular size and reduced degree of
saturation of SNAC increases membrane disorder and thus
impedes lipid mobility within the membrane.71
Once the role of PE concentration in lipid diffusivity was
established (using hybrid POPC−PE membranes), pure POPC
membranes were formed and subsequently incubated in SIF
media containing 100 mM caprylate, caprate, or SNAC. After
30 min incubation, FRAP analysis was performed to determine
the changes in membrane diffusivity as a result of exposure to
PEs. It was assumed that any changes to membrane diffusivity
would be linked with PE inclusion within the POPC
membrane. As demonstrated in Figure 7D, the diffusivity of
the lipid membrane was 2.5- to 3-fold greater when caprylate
and caprate were incubated with FaSSIF, compared to
incubation with FaSSIF alone. Since the concentration-
dependent studies (Figure 7A−C) proved that caprylate and
caprate increased membrane diffusivity, the increase in
diffusivity of the pure POPC membrane following PE
incubation can therefore be attributed to caprylate and caprate
insertion into the lipid membrane. However, the degree of
diffusivity enhancement when caprylate and caprate were
incubated with FeSSIF was considerably reduced compared to
that when included in FaSSIF. Again, this suggests that more
caprylate and caprate was inserted into the lipid bilayer in the
fasted state, compared to the fed state. Importantly, incubation
of the POPC membrane with caprylate was shown to increase
diffusivity to a greater degree than caprate, in both FaSSIF and
FeSSIF, and thus, it can be assumed that a greater amount of
caprylate is capable of being incorporated into the membrane,
which is hypothesized to be due to caprylate having a more
optimal chain length for membrane insertion. For SNAC, no
significant change in diffusivity was observed in either the
fasted or fed state, which further suggests that SNAC has a
reduced ability to be inserted into the POPC bilayer. Thus,
these findings using TIRF microscopy directly support our
CG-MD simulations and QCM-D findings, in that (i) both
caprylate and caprate inserted into the lipid membrane, (ii)
caprylate and caprate inserted into the membrane at a higher
extent in fasted-state conditions, (iii) caprylate inserted into
the membrane to a higher extent than caprate in both FaSSIF
and FeSSIF, and (iv) SNAC showed a poor ability to be
inserted into the lipid membrane in both FaSSIF and FeSSIF.
3.5. Molecular Understanding of Variable PE Delivery
into the Membrane. 3.5.1. Micelle Kinetics. For systems
with relatively smaller head−tail surfactant molecules, such as
bile salts, the dominant process in micelle kinetics is the
monomer insertion and expulsion, although occasional fission
and fusion of micelles can also be involved.42,73 These insertion
and expulsion rates depend on the micelle size and their
composition.42 To explore the role of micelle kinetics for
caprate in the FaSSIF and FeSSIF componentswhen it was
placed between the POPC membranewe calculated the
insertion or expulsion events occurring from the micelles.
These events are shown in Figure 8. For the FaSSIF system,
the average caprate insertion and expulsion events were 2.3
and 2.1 times higher, respectively, than those for FeSSIF.
Furthermore, for both FaSSIF and FeSSIF, the caprate
expulsion events are slightly higher than the insertion ones.
Note that, in an equilibrium state, the insertion and expulsion
events are supposedly similar.41,42 However, the caprate
insertion into the membrane changes the overall equilibrium
of the system. Over time, less caprate is available for inclusion
into the micelles, resulting in lower insertion. This also
suggests that, at any instance, the extraction compartment can
interact with the total amount of free caprate monomers
including the monomers released from the micelles in the
system. Therefore, the caprate insertion into the membrane is
affected by the insertion and expulsion processes of the micelle
kinetics.
3.5.2. Micelle Composition. To understand the effect of
micelle composition on the insertion and expulsion of caprate,
we explored how different components affected a single
expulsion event of a caprate monomer. We calculated the
potential of mean force (PMF) using umbrella sampling (US)
simulations. The PMF calculation was associated with the
change in the caprate molecule distance from the mixed
micelle surface to the water phase, which mimics a typical
expulsion event. Micelles with different compositions (Figure
9A and Supporting Table 1) were used for the US simulations.
The PMF profiles for all four micelles presented in Figure 9B
showed similar patterns. The PMF values were close to zero at
the water phase and decreased as the caprate molecules insert
into the shell region of the micelles. Note that the PMF profile
for expulsion or desorption of a surfactant from a micelle, using
the US with WHAM, often shows a decrease at a higher
Figure 8. Number of insertion and expulsion events of caprate
monomers during the simulation using simulated intestinal fluids. (A)
Fasted-state simulated intestinal fluid (FaSSIF) and (B) fed-state
simulated intestinal fluid (FeSSIF) with 100 mM caprate placed
between two model cell membranes.
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distance from the micelle due to an entropic effect.74 A phase
volume correction is therefore required using PMFcorrected =
PMFOriginal + kT (ln R). However, since we did not see such a
decrease in our PMF profiles, we did not apply this correction.
From the PMF profiles, we estimated the free energy
difference, ΔG, required to move a caprate molecule from the
micelle surface to the water phase. ΔG values were 3.2, 3.5, 4.3,
and 4.5 kcal/mol for the bile salts, caprate, oleate, and mixed
micelles, respectively. Note that a lower ΔG value favors the
insertion and expulsion of a caprate molecule from the micelle
surface. Therefore, a bile salt micelle is the most favorable for
the monomer insertion and expulsion event for the caprate
monomer. For the caprate, oleate, and mixed bile salt−
phospholipid micelles with a 4:1 ratio, the ΔG value increases
by about 1.1, 1.3, and 1.4 times, respectively, compared to the
bile salt micelles. This suggests that the micelle composition
can affect the caprate monomer expulsion from the micelle
surface. Also, among the typical intestinal fluid components,
the presence of more phospholipids in the intestinal fluid
increases the number of phospholipids in the mixed micelles or
pure phospholipid vesicles. This subsequently decreases the
caprate monomer expulsion and insertion events. Overall, the
results in this section also indicate that caprate will interact
with the membrane in a more dynamic manner in the presence
of FaSSIF than FeSSIF.
■ CONCLUSIONS
In this work, we used CG-MD to study the effect of bile
composition on the ability of membrane incorporation of PEs.
Free caprate monomers were more available in the fasted-state
fluids than the fed-state fluids. We then investigated the
interaction of three PEscaprylate, caprate, and SNACwith
a model cell membrane in the presence of human and
simulated bile compositions. Thereafter, we estimated the
number of free PE monomers interacting with the membrane.
The results revealed that caprylate and caprate were
incorporated into the membrane. The amount of caprylate
and caprate incorporated into the membrane in the presence of
FaSSIF was 1.7−2.6-fold higher than when dispersed in
FeSSIF. In contrast, SNAC molecules were mainly adsorbed
onto the membrane surface. Also, this interaction was more
pronounced in FaSSIF than FeSSIF.
These in silico results were verified using QCM-D and TIRF
microscopy. QCM-D showed that a large amount of caprylate
and caprate was incorporated into the membrane, whereas
SNAC was only adsorbed onto the lipid membrane surface.
The amount of incorporated caprate in the FaSSIF was about 2
times higher than in the FeSSIF. TIRF microscopy indicated
that the lipid diffusivity increased in a concentration-depend-
ent manner for caprylate and caprate and the diffusivity of the
membrane was 2.5−3-fold greater when caprylate and caprate
were incorporated with FaSSIF than with FaSSIF. SNAC
behaved differently, i.e., lipid diffusivity decreased in a
concentration-dependent manner, with no significant change
in diffusivity for FaSSIF or FeSSIF.
Both QCM-D and TIRF microscopy results were in
agreement with our CG-MD findings, which suggests that
transmembrane perturbation is a key mechanism by which
caprylate and caprate increase permeability. Further, bile
composition can affect the ability of caprylate and caprate to
perturb the membrane. The simulation and experimental
results also showed that the transcellular perturbation was not
the mode of action for SNAC and that bile composition did
not affect SNAC interaction with the membrane. Finally, the
CG-MD simulations in this study revealed that the
composition of the micelles present in the system can affect
the number of caprate monomers inserted into or expelled
from the micelle surface, which in turn affects the caprate
insertion into the membrane.
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Fredrik Höök − Division of Biological Physics, Chalmers
University of Technology, 412 96 Gothenburg, Sweden;
orcid.org/0000-0003-1994-5015
Per Larsson − Department of Pharmacy and The Swedish Drug
Delivery Forum (SDDF), Uppsala University, 751 23 Uppsala,
Sweden; orcid.org/0000-0002-8418-4956
Complete contact information is available at:
https://pubs.acs.org/10.1021/acs.molpharmaceut.0c00668
Funding
This study is part of the science program of the Swedish Drug
Delivery Forum (SDDF) and received financial support from
Vinnova (Dnr 2017-02690), European Research Council
(grant 638965), and Swedish Research Council (grant 2014-
3309). ÅForsk Foundation (16-463) is gratefully acknowl-
edged for the postdoctoral fellowship support and funding to
Paul Joyce. We also acknowledge funding from NordForsk for
the Nordic University Hub project #85352 (Nordic POP,
Patient-Oriented Products).
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
We gratefully acknowledge the discussion and insights
provided by the industrial partners of this project: Nigel
Davies (AstraZeneca), Andreas Hugerth (Ferring), Jens
Landström (Orexo), Lindvi Gudmundsdotter (Affibody), and
Bengt Dahlström (CTC). The computation/data handling was
enabled by resources provided by the Swedish National
Infrastructure for Computing (SNIC) at the Uppsala Multi-
disciplinary Center for Advanced Computational Science
(UPPMAX), the Center for High Performance Computing
(PDC), and the High-Performance Computing Center North
(HPC2N) partially funded by the Swedish Research Council
(grant agreement no. 2018-05973).
■ REFERENCES
(1) Maher, S.; Brayden, D. J.; Casettari, L.; Illum, L. Application of
Permeation Enhancers in Oral Delivery of Macromolecules: An
Update. Pharmaceutics 2019, 11, 41.
(2) Twarog, C.; Fattah, S.; Heade, J.; Maher, S.; Fattal, E.; Brayden,
D. J. Intestinal Permeation Enhancers for Oral Delivery of
Macromolecules: A Comparison between Salcaprozate Sodium
(SNAC) and Sodium Caprate (C 10). Pharmaceutics 2019, 11, 78.
(3) Maher, S.; Leonard, T. W.; Jacobsen, J.; Brayden, D. J. Safety and
Efficacy of Sodium Caprate in Promoting Oral Drug Absorption:
From in Vitro to the Clinic. Adv. Drug Delivery Rev. 2009, 61, 1427−
1449.
(4) Leonard, T. W.; Lynch, J.; McKenna, M. J.; Brayden, D. J.
Promoting Absorption of Drugs in Humans Using Medium-Chain
Fatty Acid-Based Solid Dosage Forms: GIPET. Expert Opin. Drug
Delivery 2006, 3, 685−692.
(5) Walsh, E. G.; Adamczyk, B. E.; Chalasani, K. B.; Maher, S.;
O’Toole, E. B.; Fox, J. S.; Leonard, T. W.; Brayden, D. J. Oral Delivery
of Macromolecules: Rationale Underpinning Gastrointestinal Per-
meation Enhancement Technology (GIPET). Ther. Delivery 2011, 2,
1595−1610.
(6) Aungst, B. J. Absorption Enhancers: Applications and Advances.
AAPS J. 2012, 14, 10−18.
(7) Tillman, L. G.; Geary, R. S.; Hardee, G. E. Oral Delivery of
Antisense Oligonucleotides in Man. J. Pharm. Sci. 2008, 97, 225−236.
(8) Halberg, I. B.; Lyby, K.; Wassermann, K.; Heise, T.; Zijlstra, E.;
Plum-Mörschel, L. Efficacy and Safety of Oral Basal Insulin versus
Subcutaneous Insulin Glargine in Type 2 Diabetes: A Randomised,
Double-Blind, Phase 2 Trial. Lancet Diabetes Endocrinol.. 2019, 7,
179−188.
(9) Tuvia, S.; Pelled, D.; Marom, K.; Salama, P.; Levin-Arama, M.;
Karmeli, I.; Idelson, G. H.; Landau, I.; Mamluk, R. A Novel
Suspension Formulation Enhances Intestinal Absorption of Macro-
molecules via Transient and Reversible Transport Mechanisms.
Pharm. Res. 2014, 31, 2010−2021.
(10) Leonard, T. W.; Lynch, J.; McKenna, M. J.; Brayden, D. J.
Promoting Absorption of Drugs in Humans Using Medium-Chain
Fatty Acid-Based Solid Dosage Forms: GIPET. Expert Opin. Drug
Delivery 2006, 3, 685−692.
(11) Buckley, S. T.; Vegge, A.; Pyke, C.; Ahnfelt-Rønne, J.; Madsen,
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M.; Lennernas̈, H. Effects of Absorption-Modifying Excipients on
Jejunal Drug Absorption in Simulated Fasted and Fed Luminal
Conditions. Eur. J. Pharm. Biopharm. 2019, 142, 387−395.
(28) Gradauer, K.; Nishiumi, A.; Unrinin, K.; Higashino, H.;
Kataoka, M.; Pedersen, B. L.; Buckley, S. T.; Yamashita, S. Interaction
with Mixed Micelles in the Intestine Attenuates the Permeation
Enhancing Potential of Alkyl-Maltosides.Mol. Pharmaceutics 2015, 12,
2245−2253.
(29) Riethorst, D.; Mols, R.; Duchateau, G.; Tack, J.; Brouwers, J.;
Augustijns, P. Characterization of Human Duodenal Fluids in Fasted
and Fed State Conditions. J. Pharm. Sci. 2016, 105, 673−681.
(30) Riethorst, D.; Baatsen, P.; Remijn, C.; Mitra, A.; Tack, J.;
Brouwers, J.; Augustijns, P. An In-Depth View into Human Intestinal
Fluid Colloids: Intersubject Variability in Relation to Composition.
Mol. Pharmaceutics 2016, 13, 3484−3493.
(31) Clulow, A. J.; Parrow, A.; Hawley, A.; Khan, J.; Pham, A. C.;
Larsson, P.; Bergström, C. A. S.; Boyd, B. J. Characterization of
Solubilizing Nanoaggregates Present in Different Versions of
Simulated Intestinal Fluid. J. Phys. Chem. B 2017, 121, 10869−10881.
(32) Rodríguez-Pulido, A.; Casado, A.; Muñoz-Úubeda, M.;
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Hess, B.; Lindah, E. Gromacs: High Performance Molecular
Simulations through Multi-Level Parallelism from Laptops to
Supercomputers. SoftwareX 2015, 1−2, 19−25.
(52) Parrow, A.; Larsson, P.; Augustijns, P.; Bergström, C. A. S.
Molecular Dynamics Simulations on Interindividual Variability of
Intestinal Fluids: Impact on Drug Solubilization Mol. Pharmaceutics
2020, DOI: 10.1021/acs.molpharmaceut.0c00588.
(53) Martínez, L.; Andrade, R.; Birgin, E. G.; Martínez, J. M.
Packmol: A Package for Building Initial Configurations for Molecular
Dynamics Simulations. J. Comput. Chem. 2009, 20, 2157−2164.
(54) Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.;
DiNola, A.; Haak, J. R. Molecular Dynamics with Coupling to an
External Bath. J. Chem. Phys. 1984, 81, 3684−3690.
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://dx.doi.org/10.1021/acs.molpharmaceut.0c00668
Mol. Pharmaceutics 2020, 17, 4226−4240
4239
(55) Koichi, K.; Michiya, F.; Makoto, N. Lipid Components of Two
Different Regions of an Intestinal Epithelial Cell Membrane of Mouse.
Biochim. Biophys. Acta, Lipids Lipid Metab 1974, 369, 222−233.
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